Bruker (Bruker) Cash And Cash Equivalents

: $488 Mil (As of Dec. 2023)

View and export this data going back to 2000. Start your Free Trial

Bruker's quarterly cash and cash equivalents declined from Jun. 2023 ($574.80 Mil) to Sep. 2023 ($363.60 Mil) but then increased from Sep. 2023 ($363.60 Mil) to Dec. 2023 ($488.30 Mil).

Bruker's annual cash and cash equivalents declined from Dec. 2021 ($1,068.20 Mil) to Dec. 2022 ($645.50 Mil) and declined from Dec. 2022 ($645.50 Mil) to Dec. 2023 ($488.30 Mil).

Bruker Cash And Cash Equivalents Historical Data

The historical data trend for Bruker's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bruker Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash And Cash Equivalents

678.30

681.80

1,068.20

645.50

488.30

Bruker Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash And Cash Equivalents																645.50	597.90	574.80	363.60	488.30

Bruker Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Bruker (NAS:BRKR) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Bruker Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Bruker's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Bruker (Bruker) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Bruker Corp (NAS:BRKR) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

BKD:Germany

Address

40 Manning Road, Billerica, MA, USA, 01821

Website

https://www.bruker.com

Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, pharmaceutical, and biotechnology industries. It operates in four operating segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano and Bruker Energy and Supercon Technologies (BEST). The company generates maximum revenue from the BSI CALID segment. Geographically, it derives a majority of its revenue from Europe.

Executives

Frank H Laukien	director, 10 percent owner, officer: CEO, President	C/O BRUKER DALTONICS, 40 MANNING ROAD, BILLERICA MA 01821
Marc A Kastner	director	BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Cynthia M Friend	director	C/O BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Richard A Packer	director	9 KENDALL DRIVE, WESTBOROUGH MA 01581
Philip Ma	director	C/O BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Mark Munch	officer: Pres. Bruker Nano Inc.	BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Juergen Srega	officer: Group President Bruker CALID	BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Burkhard Prause	officer: Pres. & CEO, Bruker EST	BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Bonnie H Anderson	director	6000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Martin Gilles Gerard Jean	director	BRUKER CORPORATION, 40 MANNING ROAD, BILLERICA MA 01821
Falko Busse	officer: President, BioSpin Group	40 MANNING ROAD, BILLERICA MA 01821
Gerald N Herman	officer: Vice President, Corp Contr.	55 EXECUTIVE DRIVE, HUDSON NH 03051
Ingen Chris Van	director	395 PAGE MILL RD, MS A3 18, PALO ALTO CA 94306
Richard Kniss	director	395 PAGE MILL RD, MS A3 18, PALO ALTO CA 94306
Adelene Q Perkins	director	C/O INFINITY PHARMACEUTICALS, INC., 780 MEMORIAL DRIVE, CAMBRIDGE MA 02139